Study details
Enrolling now
A Study of HLD-0117 in Patients With Metastatic Breast Cancer
Halda Therapeutics OpCo, Inc.
NCT IDNCT07524855ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18+
Sex
Female only
Locations
3 sites in FL, TN, VA
About this study
This Phase 1 study is focused on people with breast cancer. The primary outcome being measured is AEs, ECGs, Labs and Clinical Changes.
Based on ClinicalTrials.gov records.
PhasePhase 1
Primary goalAEs, ECGs, Labs and Clinical Changes
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: AEs, ECGs, Labs and Clinical Changes, Dose Limiting Toxicities (DLTs)
Secondary: Disease Control Rate (DCR), Duration of response (DOR), Objective response rate (ORR), Progression-free survival (rPFS)
Body systems
Oncology